U.S. senators warn Pentagon against downgrading Havana Syndrome response team

Two senators from opposite parties have formally challenged Defense Department plans that could rehouse the unit coordinating the U.S. government’s response to Anomalous Health Incidents, often called Havana Syndrome. Their message to Defense leadership is blunt: altering the team’s placement or stripping resources would do real harm to service members and other officials who rely on a single point of contact for medical access, benefits navigation and technical follow-up. The contested unit serves as a clearinghouse for victims seeking care and compensation and links medical follow-up with investigative work into possible causes. Lawmakers say moving that function into a different bureaucratic line could atomize responsibilities and slow progress on attribution and treatment research. The debate is occurring against a backdrop of hundreds—more than a thousand, by some tallies—reported incidents over recent years and several hundred who have sought care through military health channels, which keeps the program politically sensitive. A recent intelligence appraisal limited the likelihood that a foreign power is the main driver for most cases, but scientific panels and departmental testing of a pulsed radio-frequency device have left open technical explanations for subsets of incidents. The senators emphasize that the team’s continuity and visibility inside the department matter as much as funding, since access to decision-makers and regular briefings shape policy and patient outcomes. Critics inside and outside government fear that a reorganization framed as administrative could, in practice, reduce the team’s authority and make it harder for victims to obtain consistent care and for researchers to pursue leads. Leaders at the top of the Pentagon have publicly pledged support for continued care, yet some mid-level offices, according to congressional sources, have shown less enthusiasm for the specialized inquiry. The senators also point to statutory and oversight obligations, arguing changes should not conflict with commitments given to Congress or the expectations of affected personnel. If implemented without careful safeguards, the reconfiguration could introduce new friction into investigations and slow benefits processing at a moment when plaintiffs and scientists are pressing for clarity. The letter is both a procedural pushback and a signal that Congress will monitor any moves that dilute the team’s mission.